Allarity Therapeutics, Inc.
ALLR evidence brief
What we can confirm
- BioSniper Score:
- 3.5 / 10
- Market Cap:
- $19.4M
- Lead Asset:
- stenoparib (Phase 2)
What it means
What to watch
Prepared research question
What matters most for ALLR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ALLR
Allarity Therapeutics, Inc. (ALLR) is a Phase 2 clinical-stage pharmaceutical company developing stenoparib, a dual PARP and WNT pathway inhibitor, for advanced ovarian cancer and relapsed small cell lung cancer, supported by a proprietary Drug Response Predictor (DRP®) companion diagnostic.
Key risk: No revenue and ongoing losses
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$19.4M
Cash Runway
—
Lead Asset
stenoparib (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 3 clinical trials for Allarity Therapeutics, Inc..
Allarity Therapeutics, Inc. (ALLR) is a Phase 2 clinical-stage pharmaceutical company developing stenoparib, a dual PARP and WNT pathway inhibitor, for advanced ovarian cancer and relapsed small cell lung cancer, supported by a proprietary Drug Response Predictor (DRP®) companion diagnostic.
- Allarity is a Phase 2 clinical-stage company focused on stenoparib (2X-121), a dual PARP and WNT pathway inhibitor [news · published 2026-05-15].
- As of June 30, 2026, the company reported cash & equivalents of $17.0M, zero revenue, net income of -$3.4M, and shareholders' equity of $3.5M [sec].
- Stenoparib has FDA Fast Track designation for advanced ovarian cancer and is being studied in a Phase 2 trial with DRP®-guided patient selection [news · published 2026-05-15].
- A collaborative Phase 2 trial of stenoparib with temozolomide in relapsed small cell lung cancer is open at 11 VA sites, fully funded by the U.S. Department of Veterans Affairs [news · published 2026-02-03].
- Allarity obtained CLIA certification for its in-house laboratory and was awarded a U.S. patent protecting stenoparib exclusivity when used with its DRP® companion diagnostic into 2042 [news · published 2026-08-14].
What works
- Stenoparib has FDA Fast Track designation for advanced ovarian cancer, which may accelerate regulatory review [news · published 2026-05-15].
- The company secured a $20M non-convertible debt financing in March 2026, extending cash runway into mid-2028 [news · published 2026-03-06].
- A U.S. patent protects stenoparib exclusivity when used with its DRP® companion diagnostic into 2042, providing a potential commercial moat [news · published 2026-08-14].
- The collaborative VA Phase 2 trial in SCLC is fully funded by the VA, reducing Allarity's financial burden for that study [news · published 2026-02-03].
What to weigh
- Allarity has no reported revenue and reported a net loss of $3.4M for the quarter ending June 30, 2026 [sec].
- The company's cash position declined from $29.8M as of March 31, 2026 to $26.9M as of June 30, 2026, indicating ongoing cash burn [news · published 2026-05-15][news · published 2026-08-14].
- Stenoparib is still in Phase 2 development for both lead indications, with no approved products and no guarantee of future approval [pipeline].
- The competitive landscape for SCLC includes multiple Phase 3 programs from larger companies (e.g., PharmaMar, GSK, Daiichi Sankyo), which may limit stenoparib's market potential [pipeline].
From the filings
Quoted directly from source documents.
Stenoparib is a dual PARP and WNT pathway inhibitor
“differentiated, dual PARP and WNT pathway inhibitor”
News · May 15, 2026
FDA Fast Track designation for advanced ovarian cancer
“under FDA Fast Track designation, in advanced ovarian cancer”
News · May 15, 2026
U.S. patent protecting stenoparib exclusivity into 2042
“Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP® companion diagnostic into 2042”
News · August 14, 2026
Catalyst timeline
- 2021-03-01 · Phase 2 start for ixabepilone DRP in breast cancer — Phase II study of ixabepilone in metastatic breast cancer selected by DRP; not directly related to stenoparib.
- 2023-03-08 · Phase 1 start for 2X-121 monotherapy and combination with dovitinib — Phase Ib study to determine MTD of 2X-121 monotherapy and in combination with dovitinib in advanced solid tumors.
Risks & what to watch (4)›
Key risks
- No revenue and ongoing losses — Allarity reported zero revenue and a net loss of $3.4M for the quarter ending June 30, 2026 [sec].
- Cash burn and declining reserves — Cash declined from $29.8M (Mar 31, 2026) to $26.9M (Jun 30, 2026), indicating continued operational spending [news].
- Phase 2 clinical risk — Stenoparib remains in Phase 2 for both lead indications; no approved products exist [pipeline].
- Intense competition in SCLC — SCLC competitive landscape includes multiple Phase 3 programs from large pharma (e.g., GSK, Daiichi Sankyo) [pipeline].
What to watch
- Phase 2 ovarian cancer trial results and any updates on DRP®-guided patient selection [news · published 2026-06-18].
- Progress of the VA-funded Phase 2 SCLC combination trial with temozolomide [news · published 2026-02-03].
- Cash runway and any additional financing or partnership announcements [news · published 2026-03-06].
- Regulatory milestones, including potential pivotal trial initiation for stenoparib [news · published 2026-03-06].
Sources: Catalysts · News · Pipeline · Generated October 11, 2026 · How we verify sources →
Run Allarity Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Allarity Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 8.08
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of Apr 21, 2026- % of float
- 2.2%
- Days to cover
- 2.0
- Shares short
- 353,879
- Daily short volume (May 20, 2026)
- 65.2%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ALLR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Allarity Therapeutics, Inc.?
Allarity Therapeutics, Inc. (ALLR) is a Phase 2 clinical-stage pharmaceutical company developing stenoparib, a dual PARP and WNT pathway inhibitor, for advanced ovarian cancer and relapsed small cell lung cancer, supported by a proprietary Drug Response Predictor (DRP®) companion diagnostic.
What is Allarity Therapeutics, Inc.'s lead drug candidate?
Allarity Therapeutics, Inc.'s most advanced tracked candidate is stenoparib (Phase 2) for Advanced, recurrent ovarian cancer; Platinum resistant or platinum ineligible ovarian cancer (PROC); Relapsed Small Cell Lung Cancer (SCLC).
Who is the CEO of Allarity Therapeutics, Inc.?
Mr. Thomas H. Jensen is the chief executive officer of Allarity Therapeutics, Inc. (ALLR).
Where is Allarity Therapeutics, Inc. headquartered?
Allarity Therapeutics, Inc. (ALLR) is headquartered in Tarpon Springs, FL, United States.
What therapeutic areas does Allarity Therapeutics, Inc. focus on?
Allarity Therapeutics, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.